Thu, July 15, 2010
Wed, July 14, 2010
Tue, July 13, 2010
Mon, July 12, 2010
Fri, July 9, 2010
Thu, July 8, 2010
Wed, July 7, 2010
Tue, July 6, 2010
Mon, July 5, 2010
Fri, July 2, 2010
Thu, July 1, 2010
Wed, June 30, 2010
Tue, June 29, 2010
Mon, June 28, 2010
Sat, June 26, 2010
Fri, June 25, 2010
Thu, June 24, 2010

Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine

  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. bility-of-universal-papilloma-virus-vaccine.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

BERKELEY, CA--(Marketwire - July 6, 2010) - Dynavax Technologies Corporation (NASDAQ: [ DVAX ]) today announced the award of a $600,000 grant from the National Institutes of Health (NIH) to explore the feasibility of developing a universal vaccine to prevent infection by human papilloma virus (HPV). In contrast to the two approved HPV vaccines that target approximately 70 percent of HPV strains, Dynavax's goal is to develop a vaccine that provides immunity to nearly all cancer-causing strains of HPV. Each year, 470,000 cervical cancers are diagnosed worldwide, and 250,000 deaths are due to cervical cancers.

About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV™, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit [ www.dynavax.com ].